Diana Tudor

Dr. Diana Tudor

"Iuliu Hatieganu" University of Medicine and Pharmacy, Physiology Department, Cluj Napoca, Romania
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2020 in Cancer Biology & Medicine
Verified
Journal Article
Open access
PDF file
Diana TudorDiana Tudor
Diana Tudor
IBIoana Bâldea
Ioana Bâldea
MLMihai Lupu
Mihai Lupu
TKTeodor Kacso
Teodor Kacso
EKEniko Kutasi
Eniko Kutasi
AFAdriana Gabriela Filip
Adriana Gabriela Filip
COX-2 as a potential biomarker and therapeutic target in melanoma

9 March 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Diana TudorDiana Tudor
Diana Tudor
INIuliana Nenu
Iuliana Nenu
Gabriela Adriana FilipGabriela Adriana Filip
Gabriela Adriana Filip
EOElena Diana Olteanu
Elena Diana Olteanu
Mihai CenariuMihai Cenariu
Mihai Cenariu
IBIoana Baldea
Ioana Baldea
Melanoma therapy is challenging, especially in advanced cases, due to multiple developed tumor defense mechanisms. Photodynamic therapy (PDT) might represent an adjuvant treatment, because of its bimodal action: tumor destruction and immune system awakening. In this study, a combination of PDT mediated by a metal substituted phthalocyanine—Gallium phthalocyanine chloride (GaPc) and Metformin was used against melanoma. The study aimed to: (1) find the anti-melanoma efficacy of GaPc-PDT, (2) assess possible beneficial effects of Metformin addition to PDT, (3) uncover some of the mechanisms underlining cell killing and anti-angiogenic effects. Two human lightly pigmented melanoma cell lines: WM35 and M1/15 subjected to previous Metformin exposure were treated by GaPc-PDT. Cell viability, death mechanism, cytoskeleton alterations, oxidative damage, were assessed by means of colorimetry, flowcytometry, confocal microscopy, spectrophotometry, ELISA, Western Blotting. GaPc proved an efficient photosensitizer. Metformin addition enhanced cell killing by mechanisms dependent on the cell line, namely apoptosis in the metastatic M1/15 and necrosis in the radial growth phase, WM35. Cell death mechanism relied on the inhibition of nuclear transcription factor (NF)-κB activation and tumor necrosis factor (TNF)—related apoptosis-inducing ligand (TRAIL) sensitization, leading to TRAIL and TNF-α induced apoptosis. Metformin diminished the anti-angiogenic effect of PDT. Metformin addition to GaPc-PDT increased tumor cell killing through enhanced oxidative damage and induction of proapoptotic mechanisms, but altered PDT anti-angiogenic effects. Combination of Metformin and PDT might represent a solution to enhance the efficacy, leading to a potential adjuvant role of PDT in melanoma therapy.

18 August 2015 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
INIuliana Nenu
Iuliana Nenu
Diana TudorDiana Tudor
Diana Tudor
Gabriela Adriana FilipGabriela Adriana Filip
Gabriela Adriana Filip
IBIoana Baldea
Ioana Baldea

Verified
Journal Article
Open access
PDF file
Diana TudorDiana Tudor
Diana Tudor
IBIoana Baldea
Ioana Baldea
EOElena Diana Olteanu
Elena Diana Olteanu
EFEva Fischer-Fodor
Eva Fischer-Fodor
PVPiroska Virag
Piroska Virag
Gabriela Adriana FilipGabriela Adriana Filip
Gabriela Adriana Filip
Background: Melanoma patients stop responding to targeted therapies mainly due to mitogen activated protein kinase (MAPK) pathway re-activation, phosphoinositide 3 kinase/the mechanistic target of rapamycin (PI3K/mTOR) pathway activation or stromal cell influence. The future of melanoma treatment lies in combinational approaches. To address this, our in vitro study evaluated if lower concentrations of Celecoxib (IC50 in nM range) could still preserve the chemopreventive effect on melanoma cells treated with trametinib. Materials and Methods: All experiments were conducted on SK-MEL-28 human melanoma cells and BJ human fibroblasts, used as co-culture. Co-culture cells were subjected to a celecoxib and trametinib drug combination for 72 h. We focused on the evaluation of cell death mechanisms, melanogenesis, angiogenesis, inflammation and resistance pathways. Results: Low-dose celecoxib significantly enhanced the melanoma response to trametinib. The therapeutic combination reduced nuclear transcription factor (NF)–kB (p < 0.0001) and caspase-8/caspase-3 activation (p < 0.0001), inhibited microphthalmia transcription factor (MITF) and tyrosinase (p < 0.05) expression and strongly down-regulated the phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) signaling pathway more significantly than the control or trametinib group (p < 0.0001). Conclusion: Low concentrations of celecoxib (IC50 in nM range) sufficed to exert antineoplastic capabilities and enhanced the therapeutic response of metastatic melanoma treated with trametinib.

29 April 2015 in Medicine and Pharmacy Reports
Verified
Journal Article
Open access
PDF file
IBIoana Baldea
Ioana Baldea
Rodica-Mariana IonRodica-Mariana Ion
Rodica-Mariana Ion
EOElena Diana Olteanu
Elena Diana Olteanu
INIuliana Nenu
Iuliana Nenu
Diana TudorDiana Tudor
Diana Tudor
Gabriela Adriana FilipGabriela Adriana Filip
Gabriela Adriana Filip
Melanoma, a cancer that arises from melanocytes, is one of the most unresponsive cancers to known therapies and has a tendency to produce early metastases. Several studies showed encouraging results of the efficacy of photodynamic therapy (PDT) in melanoma, in different experimental settings in vitro and in vivo,as well as several clinical reports.Aims. Our study focuses on testing the antimelanoma efficacy of several new, synthetic photosensitisers (PS), from two different chemical classes, respectively four porphyrins and six phthalocyanines. Methods. These PS were tested in terms of cell toxicity and phototoxicity against a radial growth phase melanoma cell line (WM35), in vitro. Cells were exposed to different concentrations of the PS for 24h, washed, then irradiatied with red light (630 nm) 75 mJ/cm2 for the porphyrins and 1 J/cm2 for the phthalocyanins. Viability was measured using the MTS method.Results. Two of the synthetic porphyrins, TTP and THNP, were active photosensitizers against WM35 melanoma in vitro. Phthalocyanines were effective in producing a dose dependent PDT-induced decrease in viability in a dose-dependent manner. The most efficient was Indium (III) Phthalocyanine chloride, a metal substituted phthalocyanine.Conclusions. The most efficient photosensitizers for PDT in melanoma cells were the phthalocyanines in terms of tumor cell photokilling and decreased dark toxicity.

3 December 2023 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
INIuliana Nenu
Iuliana Nenu
IBIoana Baldea
Ioana Baldea
CCCamelia Alexandra Coada
Camelia Alexandra Coada
Rares CraciunRares Craciun
Rares Craciun
RMRemus Moldovan
Remus Moldovan
Gabriela Adriana FilipGabriela Adriana Filip
Gabriela Adriana Filip